ASCO 2024 - Genecast Group Inc.

ASCO 2024

2024-06-07

ID	Title
e20503	Genetic characteristics of cerebrospinal fluid-derived circulating tumor DNA in brain metastases of lung adenocarcinoma
e12559	Characterizing the 70-gene MammaPrint risk stratification in Chinese luminal type breast cancer and its correlation with clinicopathological characteristics, immune and metabolic functions
e12616	Clinical-significance of circulating tumor DNA in neoadjuvant treated luminal B breast cancer
e15623	Circulating tumor DNA for monitoring and early predicting treatment response to neoadjuvant chemotherapy in stage 2/3 rectal cancer without high risks: Subset analysis from the COPEC trial
195	Neoadjuvant Pyrotinib and Trastuzumab in HER2-positive Breast Cancer with No Early Response (NeoPaTHer): Primary Analysis of a Prospective, Multicenter, Response-adapted Study
e20041	Landscape of gene fusions and METex14 skipping in non-small cell lung carcinoma among the Chinese population: Insights from targeted RNA sequencing
L20	Incidence and genomic characteristics of gene fusions in a large Chinese colorectal cancer cohort
e20073	Predicting pathological response to neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer through liquid biopsy
e12619	Efficacy and biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple negative breast cancer: A prospective multicenter cohort study
e12622	Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage l-lII HER2 negative luminal B breast cancer (DANCER): Preliminary findings from an ongoing phase II study

Back